Pembrolizumab After ASCT for Hodgkin Lymphoma DLBCL and T-NHL
This phase II study is designed to determine the clinical efficacy of PD-1 blockade, using the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation therapy after autologous stem cell transplant (ASCT), in patients with relapsed or refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL), classical Hodgkin Lymphoma (cHL) or peripheral T-cell lymphoma (PTCL) in 1st remission.
A Phase 2 Study of pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma and T- Cell non-Hodgkin Lymphoma
- ClinicalTrials.gov Identifier: NCT02362997
- Protocol Number: 14-566
- Principal Investigator: Robin Joyce
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required